Investigation of soluble and transmembrane CTLA-4 isoforms in serum and microvesicles

Journal of Immunology

Volumn 193, Issue 2, 2014, Pages 889-900

  Esposito, Laura ^a,b   Hunter, Kara M D ^a,b   Clark, Jan ^a,b   Rainbow, Daniel B ^a,b   Stevens, Helen ^a,b   Denesha, Jennifer ^a,b   Duley, Simon ^a,b   Dawson, Sarah ^a,b   Coleman, Gillian ^a,b   Nutland, Sarah ^a,b   Bell, Gwynneth L ^a,b   Moran, Carla ^b,c   Pekalski, Marcin ^a,b   Todd, John A ^a,b   Wicker, Linda S ^a,b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b National Institute for Health Research Cambridge Biomedical Research Centre Addenbrooke's Hospital ^*  (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; CARBOXY TERMINAL SEQUENCE; CD4+ T LYMPHOCYTE; CELL VACUOLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GRAVES DISEASE; HUMAN; HUMAN CELL; IN VITRO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MICROVESICLE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; T LYMPHOCYTE ACTIVATION;

ADULT; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; BLOTTING, WESTERN; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CTLA-4 ANTIGEN; CYTOPLASMIC VESICLES; DIABETES MELLITUS, TYPE 1; FEMALE; GRAVES DISEASE; HELA CELLS; HUMANS; IMMUNOASSAY; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MICROSCOPY, IMMUNOELECTRON; MIDDLE AGED; PROTEIN ISOFORMS; SOLUBILITY; YOUNG ADULT;

EID: 84904254890     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1303389     Document Type: Article

References (69)

1. Tivol, E. A., F. Borriello, A. N. Schweitzer, W. P. Lynch, J. A. Bluestone, and A. H. Sharpe. 1995. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3: 541-547.
2. Walunas, T. L., D. J. Lenschow, C. Y. Bakker, P. S. Linsley, G. J. Freeman, J. M. Green, C. B. Thompson, and J. A. Bluestone. 1994. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1: 405-413.
3. Waterhouse, P., J. M. Penninger, E. Timms, A. Wakeham, A. Shahinian, K. P. Lee, C. B. Thompson, H. Griesser, and T. W. Mak. 1995. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270: 985-988.
4. + regulatory T cells abrogates their function in vivo. J. Immunol. 177: 4376-4383.
5. (+) regulatory cells that control intestinal inflammation. J. Exp. Med. 192: 295-302.
6. Wing, K., Y. Onishi, P. Prieto-Martin, T. Yamaguchi, M. Miyara, Z. Fehervari, T. Nomura, and S. Sakaguchi. 2008. CTLA-4 control over Foxp3+ regulatory T cell function. Science 322: 271-275.
7. Oaks, M. K., K. M. Hallett, R. T. Penwell, E. C. Stauber, S. J. Warren, and A. J. Tector. 2000. A native soluble form of CTLA-4. Cell. Immunol. 201: 144-153. (Pubitemid 30396226)
8. Magistrelli, G., P. Jeannin, N. Herbault, A. Benoit De Coignac, J. F. Gauchat, J. Y. Bonnefoy, and Y. Delneste. 1999. A soluble form of CTLA-4 generated by alternative splicing is expressed by nonstimulated human T cells. Eur. J. Immunol. 29: 3596-3602. (Pubitemid 29527807)
9. Darlington, P. J., M. G. Kirchhof, G. Criado, J. Sondhi, and J. Madrenas. 2005. Hierarchical regulation of CTLA-4 dimer-based lattice formation and its biological relevance for T cell inactivation. J. Immunol. 175: 996-1004. (Pubitemid 41094984)
10. Ueda, H., J. M. Howson, L. Esposito, J. Heward, H. Snook, G. Chamberlain, D. B. Rainbow, K. M. Hunter, A. N. Smith, G. Di Genova, et al. 2003. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 423: 506-511. (Pubitemid 36648570)
11. Pérez-García, A., G. Osca, A. Bosch-Vizcaya, N. Kelleher, N. Y. Santos, R. Rodríguez, Y. González, J. M. Roncero, R. Coll, M. Serrando, et al. 2013. Kinetics of the CTLA-4 isoforms expression after T-lymphocyte activation and role of the promoter polymorphisms on CTLA-4 gene transcription. Hum. Immunol. 74: 1219-1224.
12. Wicker, L. S., G. Chamberlain, K. Hunter, D. Rainbow, S. Howlett, P. Tiffen, J. Clark, A. Gonzalez-Munoz, A. M. Cumiskey, R. L. Rosa, et al. 2004. Fine mapping, gene content, comparative sequencing, and expression analyses support Ctla4 and Nramp1 as candidates for Idd5.1 and Idd5.2 in the nonobese diabetic mouse. J. Immunol. 173: 164-173. (Pubitemid 38797338)
13. Barrett, J. C., D. G. Clayton, P. Concannon, B. Akolkar, J. D. Cooper, H. A. Erlich, C. Julier, G. Morahan, J. Nerup, C. Nierras, et al. 2009. Genomewide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nat. Genet. 41: 703-707.
14. Plant, D., E. Flynn, H. Mbarek, P. Dieudé, F. Cornelis, L. Arlestig, S. R. Dahlqvist, G. Goulielmos, D. T. Boumpas, P. Sidiropoulos, et al. 2010. Investigation of potential non-HLA rheumatoid arthritis susceptibility loci in a European cohort increases the evidence for nine markers. Ann. Rheum. Dis. 69: 1548-1553.
15. Smyth, D. J., V. Plagnol, N. M. Walker, J. D. Cooper, K. Downes, J. H. Yang, J. M. Howson, H. Stevens, R. McManus, C. Wijmenga, et al. 2008. Shared and distinct genetic variants in type 1 diabetes and celiac disease. N. Engl. J. Med. 359: 2767-2777.
16. Stahl, E. A., S. Raychaudhuri, E. F. Remmers, G. Xie, S. Eyre, B. P. Thomson, Y. Li, F. A. Kurreeman, A. Zhernakova, A. Hinks, et al. 2010. Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat. Genet. 42: 508-514.
17. Atabani, S. F., C. L. Thio, S. Divanovic, A. Trompette, Y. Belkaid, D. L. Thomas, and C. L. Karp. 2005. Association of CTLA4 polymorphism with regulatory T cell frequency. Eur. J. Immunol. 35: 2157-2162. (Pubitemid 41015054)
18. Oaks, M. K., and K. M. Hallett. 2000. Cutting edge: a soluble form of CTLA-4 in patients with autoimmune thyroid disease. J. Immunol. 164: 5015-5018. (Pubitemid 30305171)
19. Liu, M. F., C. R. Wang, P. C. Chen, and L. L. Fung. 2003. Increased expression of soluble cytotoxic T-lymphocyte-associated antigen-4 molecule in patients with systemic lupus erythematosus. Scand. J. Immunol. 57: 568-572.
20. Toussirot, E., P. Saas, M. Deschamps, F. Pouthier, L. Perrot, S. Perruche, J. Chabod, P. Tiberghien, and D. Wendling. 2009. Increased production of soluble CTLA-4 in patients with spondylarthropathies correlates with disease activity. Arthritis Res. Ther. 11: R101.
21. Simone, R., R. Brizzolara, A. Chiappori, F. Milintenda-Floriani, C. Natale, L. Greco, M. Schiavo, M. Bagnasco, G. Pesce, and D. Saverino. 2009. A functional soluble form of CTLA-4 is present in the serum of celiac patients and correlates with mucosal injury. Int. Immunol. 21: 1037-1045.
22. Chen, Z., F. Zhou, S. Huang, T. Jiang, L. Chen, L. Ge, and B. Xia. 2011. Association of cytotoxic T lymphocyte associated antigen-4 gene (rs60872763) polymorphism with Crohn's disease and high levels of serum sCTLA-4 in Crohn's disease. J. Gastroenterol. Hepatol. 26: 924-930.
23. Sato, S., M. Fujimoto, M. Hasegawa, K. Komura, K. Yanaba, I. Hayakawa, T. Matsushita, and K. Takehara. 2004. Serum soluble CTLA-4 levels are increased in diffuse cutaneous systemic sclerosis. Rheumatology 43: 1261-1266. (Pubitemid 39359301)
24. Purohit, S., R. Podolsky, C. Collins, W. Zheng, D. Schatz, A. Muir, D. Hopkins, Y. H. Huang, and J. X. She. 2005. Lack of correlation between the levels of soluble cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) and the CT-60 genotypes. J. Autoimmune Dis. 2: 8.
25. Berry, A., M. Tector, and M. K. Oaks. 2008. Lack of association between sCTLA-4 levels in human plasma and common CTLA-4 polymorphisms. J. Negat. Results Biomed. 7: 8.
26. Tector, M., B. O. Khatri, K. Kozinski, K. Dennert, and M. K. Oaks. 2009. Biochemical analysis of CTLA-4 immunoreactive material from human blood. BMC Immunol. 10: 51.
27. Caby, M. P., D. Lankar, C. Vincendeau-Scherrer, G. Raposo, and C. Bonnerot. 2005. Exosomal-like vesicles are present in human blood plasma. Int. Immunol. 17: 879-887. (Pubitemid 41417955)
28. Crescitelli, R., C. Lässer, T. G. Szabó, A. Kittel, M. Eldh, I. Dianzani, E. I. Buzás, and J. Lötvall. 2013. Distinct RNA profiles in subpopulations of extracellular vesicles: apoptotic bodies, microvesicles and exosomes. J. Extracell. Vesicles DOI: 10.3402/jev.v2i0.20677.
29. Thery, C., S. Amigorena, G. Raposo, and A. Clayton. 2006. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr. Protoc. Cell Biol. Chapter 3:Unit 3.22.
30. Blanchard, N., D. Lankar, F. Faure, A. Regnault, C. Dumont, G. Raposo, and C. Hivroz. 2002. TCR activation of human T cells induces the production of exosomes bearing the TCR/CD3/zeta complex. J. Immunol. 168: 3235-3241. (Pubitemid 34250383)
31. Théry, C., L. Zitvogel, and S. Amigorena. 2002. Exosomes: composition, biogenesis and function. Nat. Rev. Immunol. 2: 569-579. (Pubitemid 37328732)
32. Boscato, L. M., and M. C. Stuart. 1988. Heterophilic antibodies: a problem for all immunoassays. Clin. Chem. 34: 27-33. (Pubitemid 18039404)
33. Kaplan, I. V., and S. S. Levinson. 1999. When is a heterophile antibody not a heterophile antibody? When it is an antibody against a specific immunogen. Clin. Chem. 45: 616-618. (Pubitemid 29220321)
34. Aly, T., D. Devendra, J. Barker, E. Liu, L. Yu, and G. S. Eisenbarth. 2004. Heterophile antibodies masquerade as interferon-alpha in subjects with newonset type 1 diabetes. Diabetes Care 27: 1205-1206. (Pubitemid 38579792)
35. Brunet, J. F., F. Denizot, M. F. Luciani, M. Roux-Dosseto, M. Suzan, M. G. Mattei, and P. Golstein. 1987. A new member of the immunoglobulin superfamily - CTLA-4. Nature 328: 267-270. (Pubitemid 17108278)
36. Freeman, G. J., A. S. Freedman, J. M. Segil, G. Lee, J. F. Whitman, and L. M. Nadler. 1989. B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells. J. Immunol. 143: 2714-2722. (Pubitemid 19260086)
37. Freeman, G. J., J. G. Gribben, V. A. Boussiotis, J. W. Ng, V. A. Restivo, Jr., L. A. Lombard, G. S. Gray, and L. M. Nadler. 1993. Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. Science 262: 909-911. (Pubitemid 24014081)
38. Linsley, P. S., S. G. Nadler, J. Bajorath, R. Peach, H. T. Leung, J. Rogers, J. Bradshaw, M. Stebbins, G. Leytze, W. Brady, et al. 1995. Binding stoichiometry of the cytotoxic T lymphocyte-associated molecule-4 (CTLA-4): a disulfide-linked homodimer binds two CD86 molecules. J. Biol. Chem. 270: 15417-15424.
39. Linsley, P. S., P. M. Wallace, J. Johnson, M. G. Gibson, J. L. Greene, J. A. Ledbetter, C. Singh, and M. A. Tepper. 1992. Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science 257: 792-795.
40. Lenschow, D. J., Y. Zeng, J. R. Thistlethwaite, A. Montag, W. Brady, M. G. Gibson, P. S. Linsley, and J. A. Bluestone. 1992. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg. Science 257: 789-792.
41. Lin, H., S. F. Bolling, P. S. Linsley, R. Q. Wei, D. Gordon, C. B. Thompson, and L. A. Turka. 1993. Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion. J. Exp. Med. 178: 1801-1806. (Pubitemid 23318461)
42. Finck, B. K., P. S. Linsley, and D. Wofsy. 1994. Treatment of murine lupus with CTLA4Ig. Science 265: 1225-1227. (Pubitemid 24291979)
43. Cross, A. H., T. J. Girard, K. S. Giacoletto, R. J. Evans, R. M. Keeling, R. F. Lin, J. L. Trotter, and R. W. Karr. 1995. Long-term inhibition of murine experimental autoimmune encephalomyelitis using CTLA-4-Fc supports a key role for CD28 costimulation. J. Clin. Invest. 95: 2783-2789.
44. Tivol, E. A., S. D. Boyd, S. McKeon, F. Borriello, P. Nickerson, T. B. Strom, and A. H. Sharpe. 1997. CTLA4Ig prevents lymphoproliferation and fatal multiorgan tissue destruction in CTLA-4-deficient mice. J. Immunol. 158: 5091-5094. (Pubitemid 127681209)
45. Genant, H. K., C. G. Peterfy, R. Westhovens, J. C. Becker, R. Aranda, G. Vratsanos, J. Teng, and J. M. Kremer. 2008. Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial. Ann. Rheum. Dis. 67: 1084-1089.
46. Ruperto, N., D. J. Lovell, P. Quartier, E. Paz, N. Rubio-Pérez, C. A. Silva, C. Abud-Mendoza, R. Burgos-Vargas, V. Gerloni, J. A. Melo-Gomes, et al. 2008. Abatacept in children with juvenile idiopathic arthritis: a randomised, doubleblind, placebo-controlled withdrawal trial. Lancet 372: 383-391.
47. Kremer, J. M., A. S. Russell, P. Emery, C. Abud-Mendoza, J. Szechinski, R. Westhovens, T. Li, X. Zhou, J. C. Becker, R. Aranda, et al. 2011. Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial. Ann. Rheum. Dis. 70: 1826-1830.
48. Leffers, H. C., M. Ostergaard, B. Glintborg, N. S. Krogh, H. Foged, U. Tarp, T. Lorenzen, A. Hansen, M. S. Hansen, M. S. Jacobsen, et al. 2011. Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry. Ann. Rheum. Dis. 70: 1216-1222.
49. Takahashi, N., T. Kojima, K. Terabe, A. Kaneko, D. Kida, Y. Hirano, T. Fujibayashi, Y. Yabe, H. Takagi, T. Oguchi, et al. 2013. Clinical efficacy of abatacept in Japanese rheumatoid arthritis patients. Mod. Rheumatol. 23: 904-912.
50. Orban, T., B. Bundy, D. J. Becker, L. A. DiMeglio, S. E. Gitelman, R. Goland, P. A. Gottlieb, C. J. Greenbaum, J. B. Marks, R. Monzavi, et al. 2011. Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet 378: 412-419.
51. Vincenti, F., C. Larsen, A. Durrbach, T. Wekerle, B. Nashan, G. Blancho, P. Lang, J. Grinyo, P. F. Halloran, K. Solez, et al. 2005. Costimulation blockade with belatacept in renal transplantation. N. Engl. J. Med. 353: 770-781. (Pubitemid 41215486)
52. Takahashi, T., T. Tagami, S. Yamazaki, T. Uede, J. Shimizu, N. Sakaguchi, T. W. Mak, and S. Sakaguchi. 2000. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J. Exp. Med. 192: 303-310.
53. Théry, C., M. Boussac, P. Véron, P. Ricciardi-Castagnoli, G. Raposo, J. Garin, and S. Amigorena. 2001. Proteomic analysis of dendritic cell-derived exosomes: a secreted subcellular compartment distinct from apoptotic vesicles. J. Immunol. 166: 7309-7318. (Pubitemid 32525606)
54. Valadi, H., K. Ekström, A. Bossios, M. Sjöstrand, J. J. Lee, and J. O. Lötvall. 2007. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 9: 654-659. (Pubitemid 47214727)
55. Raposo, G., H. W. Nijman, W. Stoorvogel, R. Liejendekker, C. V. Harding, C. J. Melief, and H. J. Geuze. 1996. B lymphocytes secrete antigen-presenting vesicles. J. Exp. Med. 183: 1161-1172. (Pubitemid 26113979)
56. Raposo, G., D. Tenza, S. Mecheri, R. Peronet, C. Bonnerot, and C. Desaymard. 1997. Accumulation of major histocompatibility complex class II molecules in mast cell secretory granules and their release upon degranulation. Mol. Biol. Cell 8: 2631-2645. (Pubitemid 27528227)
57. Admyre, C., S. M. Johansson, K. R. Qazi, J. J. Filén, R. Lahesmaa, M. Norman, E. P. Neve, A. Scheynius, and S. Gabrielsson. 2007. Exosomes with immune modulatory features are present in human breast milk. J. Immunol. 179: 1969-1978.
58. Pisitkun, T., R. F. Shen, and M. A. Knepper. 2004. Identification and proteomic profiling of exosomes in human urine. Proc. Natl. Acad. Sci. USA 101: 13368-13373. (Pubitemid 39209672)
59. Gonzalez-Begne, M., B. Lu, X. Han, F. K. Hagen, A. R. Hand, J. E. Melvin, and J. R. Yates. 2009. Proteomic analysis of human parotid gland exosomes by multidimensional protein identification technology (MudPIT). J. Proteome Res. 8: 1304-1314.
60. Mittelbrunn, M., C. Gutiérrez-Vázquez, C. Villarroya-Beltri, S. González, F. Sánchez-Cabo, M. A. González, A. Bernad, and F. Sánchez-Madrid. 2011. Unidirectional transfer of microRNA-loaded exosomes from T cells to antigenpresenting cells. Nat. Commun. 2: 282.
61. Choudhuri, K., J. Llodrá, E. W. Roth, J. Tsai, S. Gordo, K. W. Wucherpfennig, L. C. Kam, D. L. Stokes, and M. L. Dustin. 2014. Polarized release of T-cell-receptor-enriched microvesicles at the immunological synapse. Nature 507: 118-123.
62. Martínez-Lorenzo, M. J., A. Anel, and S. Gamen, NMonle, I., P. Lasierra, L. Larrad, A. Piñeiro, M. A. Alava, and J. Naval. 1999. Activated human T cells release bioactive Fas ligand and APO2 ligand in microvesicles. J. Immunol. 163: 1274-1281.
63. Nolte-'t Hoen, E. N., J. P. Wagenaar-Hilbers, P. J. Peters, B. M. Gadella, W. van Eden, and M. H. Wauben. 2004. Uptake of membrane molecules from T cells endows antigen-presenting cells with novel functional properties. Eur. J. Immunol. 34: 3115-3125. (Pubitemid 39549390)
64. Xie, Y., H. Zhang, W. Li, Y. Deng, M. A. Munegowda, R. Chibbar, M. Qureshi, and J. Xiang. 2010. Dendritic cells recruit T cell exosomes via exosomal LFA-1 leading to inhibition of CD8+ CTL responses through downregulation of peptide/MHC class I and Fas ligand-mediated cytotoxicity. J. Immunol. 185: 5268-5278.
65. Wahlgren, J., Tde. L. Karlson, P. Glader, E. Telemo, and H. Valadi. 2012. Activated human T cells secrete exosomes that participate in IL-2 mediated immune response signaling. PLoS One 7: e49723.
66. Huse, M., B. F. Lillemeier, M. S. Kuhns, D. S. Chen, and M. M. Davis. 2006. T cells use two directionally distinct pathways for cytokine secretion. Nat. Immunol. 7: 247-255.
67. Oderup, C., L. Cederbom, A. Makowska, C. M. Cilio, and F. Ivars. 2006. Cytotoxic T lymphocyte antigen-4-dependent down-modulation of costimulatory molecules on dendritic cells in CD4+ CD25+ regulatory T-cell-mediated suppression. Immunology 118: 240-249. (Pubitemid 43727429)
68. Onishi, Y., Z. Fehervari, T. Yamaguchi, and S. Sakaguchi. 2008. Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation. Proc. Natl. Acad. Sci. USA 105: 10113-10118.
69. Grohmann, U., C. Orabona, F. Fallarino, C. Vacca, F. Calcinaro, A. Falorni, P. Candeloro, M. L. Belladonna, R. Bianchi, M. C. Fioretti, and P. Puccetti. 2002. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat. Immunol. 3: 1097-1101. (Pubitemid 35363664)